Search Here

Cutting-edge research conducted by a collaborative team led by the University of Birmingham and Newcastle University offers hope for children grappling with the most common malignant form of brain cancer by potentially slashing diagnostic wait times through a novel, less invasive approach.

Published in eBioMedicine, the study delved into the world of pediatric brain tumors, specifically medulloblastoma, and explores a faster and less invasive method for determining tumor type. By examining metabolic profiles unique to each of the four distinct groups of medulloblastoma, the researchers identified specific markers using cell samples from 86 tumors. This breakthrough could revolutionize the diagnosis process, particularly for children facing this aggressive cancer.

Of particular significance is the validation of previous research indicating the close association between glutamate, a metabolite present in all tumor cells, and tumor prognosis. Furthermore, the study suggested that utilizing MRI scanning in conjunction with machine learning could swiftly assess medulloblastomas for their metabolic signatures, potentially eliminating the need for invasive biopsies and drastically reducing the current 3-4 week diagnostic wait time.

Lead author of the study, Andrew Peet, Emeritus Professor of Clinical Pediatric Oncology at the University of Birmingham, noted the urgency of timely diagnosis in cancer treatment saying, "Time is so important in cancer diagnosis so our findings on different types of medulloblastoma having a detectable signature metabolism could be game changing for quickly diagnosing, and then offering the best possible treatment for children."

Echoing Peet's sentiments, Professor Steve Clifford, Chair of Molecular Pediatric Oncology at Newcastle University Center for Cancer, highlighted the transformative potential of rapid diagnosis facilitated by innovative scanning and AI techniques, which could streamline patient management and alleviate the uncertainty faced by patients and their families.

"Providing a rapid diagnosis using innovative scanning and AI (artificial intelligence) techniques, has the potential to revolutionize patient management, allowing early non-invasive diagnosis, tailoring of treatment decisions and reducing the period of uncertainty for patients and parents while awaiting a full diagnosis," Clifford said, as per Medical Express.

"Further, our biological findings provide critical new insights into the metabolism underpinning these tumors, and the potential to exploit these therapeutically."

The study's implications hit close to home for families like that of 6-year-old Jack Bourne from Birmingham, who underwent a grueling journey following his medulloblastoma diagnosis. Jack's father, Tom, shared the harrowing experience of waiting weeks for a definitive diagnosis.

"The research that's going into diagnosing tumors is really important," said Tom. "In Jack's case there was quite a delay while they sent his tumor to Great Ormond Street to be analyzed. During that time Jack was given some chemo just to start things off because they just wanted to do something rather than just wait. But all you want is for your child to be given the best possible treatment right from the start."

The groundbreaking research, funded in part by Children with Cancer UK, holds promise for improving outcomes and experiences for children and families grappling with pediatric brain tumors. Dr. Laura Danielson of Cancer Research UK stressed the importance of such discoveries in driving progress toward better detection and treatment strategies for childhood cancers.

"This important study has identified a new way to distinguish between the four subgroups of medulloblastoma. This discovery paves the way for the development of simple imaging tests that could quickly and accurately diagnose the different types of medulloblastoma," Danielson explained.

"This kind of discovery research is important to drive new and improved ways to better detect and treat cancers affecting children and young people."